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Intravenous iron is commonly used in conjunction with
erythropoietic agents to treat anemia in patients with chronic
kidney disease. Iron has been proposed to promote oxidative
stress and endothelial dysfunction in vascular tissues. We
studied the acute effects of intravenous iron sucrose on
homocysteine-induced endothelial dysfunction in the
brachial artery of normal human subjects. In all, 40 healthy
subjects received intravenous iron sucrose 100 mg or placebo
over 30 min immediately before ingestion of 100 mg/kg of
oral methionine in a double-blind, randomized study.
Flow- and nitroglycerin-mediated dilation in the brachial
artery, serum markers of iron stores, and homocysteine and
nitrotyrosine levels were measured before and after study
drug administration. Intravenous iron significantly increased
transferrin saturation and non-transferrin-bound iron (NTBI)
when compared with placebo. Flow-mediated dilation
significantly decreased from baseline 1 h after administration
of iron sucrose when compared with placebo (from
6.6670.47 to 1.9370.35% after iron sucrose vs from
6.0070.40 to 5.6170.46% after placebo, Po0.001), but did
not differ between groups at 4 h (1.1070.39 vs 1.3370.51%).
Nitroglycerin-mediated vasodilation, and homocysteine and
3-nitrotyrosine levels did not differ after administration of
iron sucrose and placebo. Intravenous administration of iron
sucrose in the setting of transient hyperhomocysteinemia
induced by methionine ingestion significantly increased
transferrin saturation and plasma levels of NTBI and
significantly attenuated flow-mediated dilation in the
brachial artery when compared with placebo. This potential
mechanistic link between intravenous iron and endothelial
dysfunction warrants further study of cardiovascular effects
of intravenous iron in anemic chronic kidney disease
populations.
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Intravenous iron preparations are commonly administered
in conjunction with erythropoietic agents for the treatment
of anemia in patients with chronic kidney disease and
functional iron deficiency.1,2 Iron is a pro-oxidant cofactor
that has been proposed to be linked to increased cardiovas-
cular risk.3–5 Observational studies of the association between
various measures of iron stores and coronary risk in general
populations and chronic kidney populations have yielded
conflicting findings.1,4,6
The vascular endothelial plays an important role in the
normal regulation of vasomotor tone, vascular structure,
and thrombosis.7 Endothelial dysfunction is associated with
increased risk of cardiac events in patients with established
atherosclerosis and hypertension.8 Intravenous iron sucrose
has been previously reported to transiently increase levels of
non-transferrin-bound iron (NTBI) in association with mild
attenuation of endothelium-dependent vasodilation in the
brachial artery of normal subjects.9 Although this observa-
tion is consistent with the overall good safety record of
intravenous iron sucrose, physiological response in normal
subjects may not be predictive of that in chronic kidney
disease populations with multiple comorbidities associated
with increased oxidative stress.1 Subjects heterozygous for the
hemochromatosis gene with modest increases in serum
ferritin levels are at increased risk for cardiovascular events,
particularly in the presence of other known risk factors such
as hypertension or cigarette smoking.10,11 Accordingly, we
hypothesized that iron may increase vascular risk by
augmenting oxidative stress in the setting of coexisting
cardiac risk factors.
Hyperhomocysteinemia induced by oral methionine
ingestion in normal subjects is associated with increased
oxidative stress and transient vascular endothelial dysfunc-
tion.12,13 Iron chelation with dexrazoxane has been shown to
attenuate homocysteine-induced endothelial dysfunction in
normal subjects, but the direct interaction between intra-
venous iron and homocysteine has not been reported
previously.14 The current study was undertaken to pros-
pectively test the hypothesis that the pro-oxidant effects of
intravenous iron sucrose would augment vascular endothelial
dysfunction induced by transient hyperhomocysteinemia
in normal subjects. We measured flow-mediated and nitro-
glycerin-mediated dilation in the brachial artery with
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2006 International Society of Nephrology
Received 14 June 2005; revised 29 July 2005; accepted 11 August 2005;
published online 4 January 2006
Correspondence: SD Katz, Department of Medicine, Yale University School
of Medicine, 135 College Street, Suite 301, New Haven, Conneticut 06510,
USA. E-mail: stuart.katz@yale.edu
Kidney International (2006) 69, 679–684 679
high-resolution ultrasound imaging and serum markers of
iron stores and oxidative stress before and after administra-
tion of intravenous iron sucrose or placebo (normal saline) in
40 healthy subjects with transient hyperhomocysteinemia
induced by methionine ingestion in a double-blind, rando-
mized trial.
RESULTS
Study drug was well tolerated with no adverse reactions
reported. Baseline characteristics of the two treatment groups
did not differ (Table 1). Serum iron, transferrin saturation,
and NTBI significantly increased after administration of iron
sucrose when compared with placebo (Table 2). NTBI levels
were highly correlated with percent transferrin saturation 4 h
after study drug administration (r¼ 0.82, Po0.001; Figure 1).
Flow-mediated dilation significantly decreased from baseline
1 h after administration of iron sucrose when compared with
placebo (from 6.6670.47 to 1.9370.35% after iron sucrose
vs from 6.0070.40 to 5.6170.46% after placebo, Po0.001
for group by time interaction; Figure 2), but did not differ
between groups at 4 h (1.1070.39 vs 1.3370.51%; Figure 2).
Brachial artery flow velocity at rest and during postischemic
hyperemia did not differ between subjects receiving iron
sucrose or placebo before study drug (rest 871 vs 971 cm/s
and hyperemia 5975 vs 6175 cm/s, both P¼NS) and at
1 and 4 h after study drug (rest 1 h 871 vs 871 cm/s
and hyperemia 1 h 5875 vs 5974 cm/s; rest 4 h 1071 vs
971 cm/s and hyperemia 4 h 5775 vs 5675 cm/s, all
comparisons P¼NS). Nitroglycerin-mediated vasodilation,
heart rate, mean arterial pressure, homocysteine, and
nitrotyrosine levels did not differ before or after administra-
tion of iron sucrose and placebo (Table 3).
Consistent with the gender-stratified randomization
code incorporated into our study design, gender distribution
in the two treatment groups did not differ (Table 1) and
adjustment for gender in multivariate analysis did not alter
the findings of the primary unadjusted analysis. Baseline
levels of ferritin and homocysteine were lower in women
when compared with men (ferritin 32 (50) vs 126 (93) ng/ml,
Po0.001 and homocysteine 6.270.5 vs 7.770.4 ng/ml,
P¼ 0.018). In multivariate analysis, the difference in flow-
mediated dilation between the iron sucrose group and
the placebo group tended to be greater in women when
Table 2 | Biomarkers of iron stores (means7s.e.m., or for ferritin median (interquartile range)) before and 4 h after
administration of iron sucrose or placebo
Iron sucrose (n=20) Placebo (n=20)
Before 4 h post Before 4 h post P-value*
Serum iron (mM) 1472 53711 1271 1671 0.001
Total iron binding capacity (mM) 4873 60711 4973 5173 0.36
% transferrin saturation 3179 8779 2472 3272 o0.001
NTBI (mM) 0.5170.09 2.5470.21 0.6470.11 0.6670.09 o0.001
Serum ferritin (ng/ml) 93 (113) 92 (213) 89 (111) 81 (117) 0.84
*P-value for treatment group-by-time interaction term in repeated measures analysis of variance model.
Table 1 | Clinical characteristics of study population by study
drug assignment (means7s.e.m.)
Iron sucrose
(n=20)
Placebo
(n=20) P-value
Age (years) 2771 2771 0.78
Gender (no. of male/no. of female) 12/8 12/8 —
Body mass index (kg/m2) 2471 2471 0.99
Total cholesterol (mg/dl) 15276 16375 0.14
Low-density cholesterol (mg/dl) 8176 9275 0.17
High-density cholesterol (mg/dl) 5374 5373 0.99
Triglycerides (mg/dl) 87715 88710 0.95
Blood glucose (mg/dl) 9273 8872 0.34
Hemoglobin (gm/dl) 14.170.3 14.070.4 0.77
Brachial artery diameter (mm) 3.5870.12 3.5870.15 0.32
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Figure 2 | Flow-mediated dilation in the brachial artery (FMD (%),
mean7s.e.m.) before and at 1 and 4 h after administration of
intravenous iron sucrose 100 mg (open squares) or placebo
(filled squares). *Po0.001 vs placebo.
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Figure 1 | Scatterplot relating transferrin saturation and plasma
levels of NTBI 4 h after study drug administration.
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compared with that in men (P¼ 0.09 for gender-by-treat-
ment interaction; Table 4).
DISCUSSION
The present data demonstrate that administration of
intravenous iron sucrose in the setting of transient hyper-
homocysteinemia induced by methionine ingestion in
healthy subjects significantly increased transferrin saturation
and plasma levels of NTBI and significantly attenuated flow-
mediated dilation (but not nitroglycerin-mediated dilation)
in the brachial artery when compared with placebo.
Iron sucrose is composed of an inner core of ferric
hydroxide sequestered by an outer sphere of sucrose mole-
cules with molecular weight of approximately 43 kDa.15 The
large majority of the iron contained within iron sucrose is
metabolized by reticuloendothelial cells in the liver, spleen,
and bone marrow, with rapid incorporation in the red blood
cell iron pool.16,17 However, 2–6% of the iron present in iron
sucrose and other intravenous iron preparations appears to
be more labile and is immediately available for binding to
plasma apotransferrin upon injection.18–20 Our finding of
increased transferrin saturation and increased NTBI after
injection of intravenous iron sucrose is in accord with
previous reports in normal subjects and patients with chronic
kidney disease.9,21–23 Although there is no consensus on the
best analytical approach for the detection of NTBI, this pool
of iron appears to be biologically active. Growth of iron-
requiring bacteria in culture is supported by the serum of
end-stage kidney disease patients treated with intravenous
iron and can be blocked by the addition of apotransferrin to
the serum.21
The current study is the first study to our knowledge that
directly tests the interaction between the effects intravenous
iron administration and transient hyperhomocysteinemia on
vascular endothelial function in the intact human circula-
tion. Previous studies have demonstrated small decreases in
flow-mediated dilation of the brachial artery 1 h after intra-
venous iron sucrose administration alone or in response to
increased homocysteine levels 1 h after methionine ingestion
alone.9,12,13,24–26 Our finding of a small decrease in flow-
mediated dilation at 1 h after administration of placebo is
in accord with these previous reports in normal subjects. In
contrast, administration of intravenous sucrose in combi-
nation with oral methionine was associated with severe
attenuation in flow-mediated dilation to levels comparable
to those reported in patients with chronic cardiovascular
diseases.8,27 Flow-mediated dilations were severely attenua-
ted in both groups and no longer significantly different at
4 h after administration of iron sucrose or placebo. The
observed decrease in flow-mediated dilation at 4 h in the
placebo group in response to increased homocysteine levels is
generally consistent with prior reports, but was larger than
anticipated based on findings from a previous study from our
laboratory.14 This large decrease in flow-mediated dilation
at 4 h in the placebo group limited our ability to detect
an interaction between iron and homocysteine at 4 h due to
a ceiling effect and reduced statistical power.
We anticipated that gender might be an important
confounding factor and prospectively stratified our random
treatment allocation scheme accordingly. As expected,
premenopausal women had lower baseline markers of
iron stores and homocysteine levels when compared with
men. Our finding of a strong trend towards a gender-by-
treatment interaction as presented in Table 4 is consistent
with our primary hypothesis of interaction between iron
and homocysteine.
Tyrosine nitration was initially proposed as a specific
marker of increased oxidative stress related to the generation
of peroxynitrite from nitric oxide.28,29 Although several
non-nitric oxide biosynthetic pathways for 3-nitrotyrosine
synthesis have also been proposed, these alternate pathways
of tyrosine nitration also involve free radical chemistry
reactions.30,31 Increased tyrosine nitration has been reported
in patients with heart failure and coronary artery disease.32,33
In the current study of normal subjects, 3-nitrotyrosine
did not change in response to intravenous iron or transient
hyperhomocysteinemia. This was an unexpected finding,
Table 3 | Brachial artery, systemic hemodynamic, and biochemical measurements (means7s.e.m., or for nitrotyrosine median
(interquartile range)) before and 4 h after administration of iron sucrose or placebo
Iron sucrose (n=20) Placebo (n=20)
Before 4 h post Before 4 h post P-value*
NTG-mediated dilation (%) 2771 2571 2771 2571 0.947
Heart rate (min1) 6072 6572 6573 6172 0.12
Mean arterial pressure (mmHg) 8271 7971 8072 7971 0.16
Plasma homocysteine (ng/ml) 7.270.4 25.271.4 7.070.5 24.771.4 0.87
Plasma nitrotyrosine (pg/ml) 5 (62) 6 (62) 11 (62) 11 (49) 0.90
*P-value for treatment group-by-time interaction term in repeated measures analysis of variance model.
NTG, nitroglycerin.
Table 4 | Flow-mediated dilation (%) before and after study
drug administration in subjects grouped by gender
Prestudy drug 1 h post 4 h post
Females (n=16)
Placebo 6.570.6 6.270.7 2.370.8
Iron sucrose 5.970.9 2.470.7 1.070.8
Males (n=24)
Placebo 5.770.5 5.270.6 0.770.4
Iron sucrose 7.270.5 1.670.3 1.170.4
Kidney International (2006) 69, 679–684 681
H Zheng et al.: Iron and endothelial function o r i g i n a l a r t i c l e
as both homocysteine and iron had been previously reported
to be associated with increased oxidative stress in experi-
mental and clinical settings.9,13,34–39 However, clinical studies
of serum markers of lipid peroxidation in response to
intravenous iron and transient hyperhomocysteinemia have
yielded conflicting findings.25,30,40,41 The lack of change in
3-nitrotyrosine in our study may be attributable to the
limited utility of serum markers for the detection of
acute changes in intracellular redox state. Alternatively, the
observed interaction of iron and homocysteine on endo-
thelial function may be related to effects of iron on
mitochondrial function, heme-containing enzymes, or iron-
responsive intracellular signaling.19,42–44
We studied a disease model of transient homocysteine-
induced endothelial dysfunction in normal subjects that may
not be predictive of clinical responses to intravenous iron in
patients with established vascular disease. The potential
clinical sequelae of transient endothelial dysfunction in
response to intravenous iron are uncertain. However, since
endothelial dysfunction is associated with increased cardiac
risk in patients with hypertension and clinical vascular
disease,8 our findings raise concern regarding clinical
utilization of intravenous iron in patient populations at
increased cardiac risk. Current guidelines recommend intra-
venous iron to correct functional iron deficiency unrespon-
sive to oral iron supplementation in anemic patients with
end-stage renal disease.1,2 Chronic kidney disease is known to
be associated with vascular endothelial dysfunction, evidence
of increased oxidative stress, and increased risk of cardiovas-
cular events.45–49 Intravenous iron preparations (other than
iron dextran) are generally well tolerated in chronic kidney
disease patients,15,50 but have also been tentatively linked to
increased risk of cardiovascular events in some retrospective
analyses of clinical trials of erythropoietic therapy in anemic
chronic kidney disease populations.6,23,51–53
In conclusion, the current data demonstrate that intrave-
nous iron sucrose augments transient homocysteine-induced
endothelial dysfunction in normal subjects. These findings
suggest a potential mechanistic link between intravenous iron
and cardiac risk. Additional work is needed to determine the
effects of intravenous iron on endothelial function and
cardiovascular risk in anemic hemodialysis patients with
functional iron deficiency.
MATERIALS AND METHODS
Study sample
All subjects were normotensive nonsmokers with no history of
chronic illness or chronic medication use. The criteria for exclusion
were low-density lipoprotein (LDL) 4160 mg/dl, fasting blood
sugar 4110 mg/dl, plasma homocysteine 410 mmol/l, and preg-
nancy. The study protocol was approved by the Institutional Ethical
Review Committee. All subjects provided informed written consent
before participation.
Ultrasound imaging
Flow-mediated endothelium-dependent vasodilation in the brachial
artery was determined with an ATL Apogee 800 duplex ultrasound
imaging system connected to an 11 MHz high-resolution transducer
by a single blinded investigator, adapted from published guide-
lines as described previously.54,27 The brachial artery was imaged
longitudinally approximately 5 cm above the antecubital fossa.
Arterial diameter (mm) was derived from the average of five on-
screen electronic caliper measurements. External landmarks and
internal landmarks (veins, arterial branches, or distinctive soft-tissue
markings) were utilized to ensure that all measurements were
derived from the same arterial segment. Brachial artery diameter
and Doppler blood flow velocity were measured at rest and after
transient arterial occlusion induced by 5-min inflation of a fore-
arm pneumatic cuff to 200 mmHg. Flow-mediated dilatation was
calculated as the percent increase in brachial artery diameter 60 s
after the release of the occluding cuff. Endothelium-independent
vasodilation was determined as the percentage increase in brachial
diameter 5 min after administration of 0.4 mg of sublingual
nitroglycerin.
Analytical methods
Techniques for determining serum iron (SI) and deriving the total
iron binding capacity and transferrin saturation (%) are outlined as
follows:55,56 at acidic pH (acetate buffer, pH 4.5) and in the presence
of hydroxylamine (a reducing agent), transferrin-bound iron or SI
dissociates to release ferrous ions. These react with ferrozine to form
a stable magenta-colored complex (Fe2þ -ferrozine) with a max-
imum absorption at 560 nm. The difference in absorbance at 560 nm
before and after ferrozine addition in serum sample is proportional
to SI concentration. In contrast to SI, serum-unbound iron binding
capacity was measured at alkaline pH (TRIZMAs, pH 8.1). Ferrous
ions added to the serum bind specifically with transferrin at
unsaturated iron-binding sites and then remaining unbound ferrous
ions are measured with the ferrozine reaction. The difference
between the amount of unbound iron and the total amount added
to serum is equivalent to the quantity bound to transferrin, which is
the unbound iron binding capacity. The serum total iron binding
capacity equals the SI plus the unbound iron binding capacity.
Serum transferrin saturation (%) was calculated using SI divided by
total iron binding capacity 100.
Ferritin in sera was determined according to a previously
published protocol.55,57 In brief, an antibody to a mixture of human
spleen and liver ferritin was used as the capture antibody to coat an
enyme-linked immunosorbent assay plate. Human liver ferritin was
used as the standard (Roche Molecular Bio-Chemicals, Indianapolis,
IN, USA). The conjugate of peroxidase and antibody to human
spleen and liver ferritin was then added to serve as the detector to
determine the amount of ferritin bound to the capture antibody.
Tetramethylbenzidine was then added as the peroxidase substrate,
and the absorbance of the peroxidase-mediated tetramethylbenzi-
dine oxidation product was determined at 450 nm using the
UV–visible microplate reader (SpectraMax Plus, Molecular Devices,
Sunnyvale, CA, USA).
Levels of NTBI were determined using nitrilotriacetic acid to
capture iron that is nonspecifically bound to serum proteins and
low-molecular-weight ligands, without chelating transferrin- or
ferritin-bound iron.58 Sodium tris-carbonatocobaltate(III) tri-
hydrate was preincubated with serum prior to nitrilotriacetic
acid–iron complexation to block the free iron binding sites of
transferrin. This procedure is to ensure that unsaturated transferrin
will not chelate NTBI during sample preparation. After the addition
of nitrilotriacetic acid, all the NTBI is quantitatively converted to
the Fe–nitrilotriacetic acid complex, which can be monitored
682 Kidney International (2006) 69, 679–684
o r i g i n a l a r t i c l e H Zheng et al.: Iron and endothelial function
spectrophotometrically after ultracentrifugation. In brief, 350 ml
serum was incubated with 100mml 4.8 mM sodium tris-carbonato-
cobaltate(III) trihydrate at 371C for 1 h. Then, nitrilotriacetic acid
was added to the serum mixture to obtain a final concentration of
80 mM. After standing at room temperature for 30 min, the samples
were filtered through a Centricon membrane with a nominal
molecular weight limit of 30 kDa (Centricon-30) at 3000 g for 1 h.
The ultrafiltrate was then diluted at 1:1 ratio with 5 mM 3-[N-
morpholino]propane sulfonic acid buffer (pH 7.4). To form the
chromogenic complex, 110 of total reaction volume of 120 mM sodium
thioglycolic acid and 60 mM sodium bathophenanthroline disulfonic
acid (both dissolved in deionized water) was added to the solution
and allowed to stand for 30 min at room temperature. The resulting
complex was measured by spectrophotometry at 537 nm.
Total plasma homocysteine were determined in mmol/l by high-
pressure liquid chromatography.59 Nitrotyrosine was measured with
a commercially available enzyme-linked immunoabsorbent assay.
Study protocol
The study followed a randomized, double-blind, placebo-controlled
parallel group design. Study drug assignment was determined by
a blocked randomization scheme stratified by gender and held by
the research pharmacy. All subjects were studied in the fasting
state. Intravenous iron sucrose 100 mg in 250 cm3 of normal saline
(iron(III) hydroxide sucrose, Venofers, American Regent) or
250 cm3 of plain normal saline was administered over 30 min by a
member of the Yale General Clinical Research Center nursing staff.
To maintain the double-blind protocol, investigators were not
allowed inside the room at the time of the study drug infusion and
the infusion lines were covered with an opaque material.
Immediately after completion of the study drug infusion, oral
methionine 100 mg/kg mixed in fruit juice was administered. Flow-
mediated dilation in the brachial artery was determined before and
at 1 and 4 h after study drug administration. Nitroglycerin-mediated
dilation in the brachial artery, and venous blood for serum markers
of iron stores, homocysteine and nitrotyrosine levels were obtained
before and 4 h after study drug administration. Plasma was
separated from venous blood by cold centrifugation and stored at
801C until analysis.
Statistical analysis
Descriptive statistics were used to determine means and distribu-
tions of clinical characteristics and physiological and laboratory
measurements in the study sample. Continuous variables with
normal distributions are presented as means7s.e.m. in the text and
tables. Serum ferritin and nitrotyrosine levels were noted to
significantly deviate from the normal distribution (by Shapiro–Wilk
test), so the natural logarithm of these variables was used in all
analyses; median values and interquartile range for these variables
are presented in the text and tables. Unpaired Student’s t-tests and
w2 tests were used to compare means and proportions of baseline
clinical and laboratory characteristics, respectively, in the two
treatment groups. Differences in physiological and laboratory
variables in response to study drug were analyzed with a repeated
measures analysis of variance model with factors of treatment
group, time, and the interaction of treatment group-by-time (Stata
statistical software version 8.0, College Park, Austin, TX, USA).
From previous data derived from our laboratory, the anticipated
mean and standard deviation of the change in flow-mediated
dilation after administration of methionine and placebo were
2.370.8%. In all, 20 subjects per treatment arm provided 480%
power to detect a clinically relevant 30% further decrease in flow-
mediated dilation in response to methionine after iron sucrose
administration. For all analyses, a two-tailed P-value o0.05 was
used to infer statistical significance.
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